Top View
- ONGENTYS® (Opicapone) Oral
- Blue Rx Value Plus Formulary
- Opicapone Prescribing Information
- DRUG TREATMENTS for Parkinson's
- Safinamide Improves Non-Motor Symptoms Burden In
- Clinical Trial Protocol: JZP166-201 Amendment 2
- The Synthesis and Evaluation of Dual Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase
- Alphabetical Listing by Therapeutic Category Dod UNIFORM
- ONGENTYS® (Opicapone) Capsules Patient Brochure
- Safinamide – Benefit Assessment According to §35A Social Code Book V1
- Efficacy and Safety of Once-Daily Opicapone 50 Mg in Patients With
- Formulary Item
- Sulfonation and Methylation in Silico - Modelling Studies on SULT1A3 and COMT
- A Treatment Guide to Parkinson's Disease
- Neurocrine Biosciences Announces FDA Approval of Once-Daily
- WO 2019/038639 Al 28 February 2019 (28.02.2019) W P O PCT
- Appendix a - Product Name Index
- LMMG New Medicine Recommendation
- Absorption, Metabolism, and Excretion, in Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator S
- Medical Necessity Criteria for Pharmacy Edits, 5.01.605
- Alphabetical Listing by Name Dod UNIFORM OUTPATIENT
- A Peripheral COMT Inhibitor for the Improvement of Parkinson’S Disease Patients with Motor Fluctuations
- Shared Care Guideline for Prescribing Entacapone
- Risk Assessment and Risk Mitigation Review(S)
- Ongentys) Reference Number: ERX.NPA.144 Effective Date: 09.01.20 Last Review Date: 08.20 Line of Business: Commercial, Medicaid Revision Log
- Access Tier 4 HMO and PPO Prescription Drug List DMHC Version
- Ongentys, INN-Opicapone
- Opicapone Capsules in Parkinson’S Disease Can Be Shared Between the Specialist and General Practitioner (GP)
- Opicapone: from Preclinical Data to Real-World Evidence
- Opicapone: from Preclinical Data to Real-World Evidence
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- The Choice Is Yourstm
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Ongentys (Opicapone) – New Drug Approval
- Metal Chelation Therapy and Parkinson's Disease
- Opicapone for Parkinson's Disease
- Drug Interactions
- COMT Inhibitors
- Clinical Utility of Ongentys®(Opicapone) 50 Mg Confirmed by Real-World Data in Parkinson’S Disease Patients with Motor Fluctuations
- Ongentys 45536 Gpi-10 (7315306000)
- PA Medical Assistance Fee-For-Service Quantity Limits & Daily Dose Limits
- Ongentys, INN-Opicapone
- Patient Safety: Psychosis As the Diagnosis, Drugs As the Cause
- ONGENTYS (Opicapone) Capsules, for Oral Use • Dyskinesia: May Cause Or Exacerbate Dyskinesia; Consider Levodopa Or Initial U.S
- 212489Orig1s000
- Assessment of Tolerability and Efficacy of Opicapone in Daily Clinical Practice Vinagre-Aragón A, Mondragón-Rezola E, Bergareche-Yarza A, Croitoru I, Ruiz-Martinez J